Howard Taylor Ricketts Laboratory, Argonne National Laboratory, Lemont, IL 60649;
Department of Microbiology, University of Chicago, Chicago, IL 60637.
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19659-19664. doi: 10.1073/pnas.1911922116. Epub 2019 Aug 14.
Rickettsial diseases have long been diagnosed with serum antibodies cross-reactive against (Weil-Felix reaction). Although Weil-Felix antibodies are associated with the development of immunity, their rickettsial target and contribution to disease pathogenesis are not established. Here, we developed a transposon for insertional mutagenesis of , isolating variants defective for replication in cultured cells and in spotted fever pathogenesis. Mutations in the () abolish lipopolysaccharide O-antigen synthesis and Weil-Felix serology and alter outer-membrane protein assembly. Unlike wild-type , mutants cannot elicit bactericidal antibodies that bind O antigen. The operon is conserved among rickettsial pathogens, suggesting that bactericidal antibodies targeting O antigen may generate universal immunity that could be exploited to develop vaccines against rickettsial diseases.
立克次体病长期以来一直通过与血清抗体交叉反应的方法来诊断(魏尔-斐克斯反应)。虽然魏尔-斐克斯抗体与免疫的发展有关,但它们的立克次体靶标和对疾病发病机制的贡献尚不清楚。在这里,我们开发了一个转座子用于插入诱变 ,分离出在培养细胞和斑点热发病机制中复制缺陷的变体。在 ()中的突变消除了脂多糖 O-抗原的合成和魏尔-斐克斯血清学,并改变了外膜蛋白的组装。与野生型不同, 突变体不能诱导结合 O 抗原的杀菌抗体。该 操纵子在立克次体病原体中是保守的,这表明针对 O 抗原的杀菌抗体可能产生普遍的免疫,可用于开发针对立克次体病的疫苗。